Personalized Treatment for Eating Disorders
(T-NIPT-ED Trial)
Trial Summary
What is the purpose of this trial?
Eating disorders (EDs) are serious mental illness: someone dies of an ED every 52 minutes. EDs are highly related to a host of negative outcomes, including public health and individual disease burden, medical and psychological comorbidities, and social determinants of health (SDOH). Treatment response for EDs are suboptimal; there are no evidence-based treatment for adults with anorexia nervosa (AN) or Other Specified Feeding or Eating Disorder (OSFED) and only 50% of adults respond to current evidence based treatments. There are no precision treatments, nor any treatments that consider social context, in existence. Personalized treatments for EDs, that consider social contexts, are urgently needed to improve treatment response and minimize the suffering associated with these illnesses. The investigators' overall goal, extending upon their past work, is to create a treatment personalized based on idiographic (or one person) models (termed Transdiagnostic Network Informed Personalized Treatment for EDs; T-NIPT-ED). The investigators will carry out a two-phase study to systematically characterize individual mechanisms of treatment (Phase I: N=900) and then test the efficacy of each treatment module (Phase II: N=240 drawn from Phase I) compared to the current gold-standard treatment (Cognitive Behavioral Therapy Enhanced: CBT-E). The study goals are to (1) characterize the prevalence of T-NIPT-ED precision treatment mechanisms and medical and psychological comorbidities (e.g., obesity; depression), individual disease burden (e.g., disability), SDOH (e.g., food insecurity), and public health outcomes (e.g., service utilization) specific to these mechanisms, (2) identify if personalized target mechanisms improve when matched to evidence-based treatment modules of T-NIPT-ED and (3) test if change in T-NIPT-ED is associated with improved outcomes (vs CBT-E), including ED outcomes, comorbidities, disease burden, and public health outcomes and if these outcomes are moderated by SDOH. These goals will ultimately lead to the very first precision treatment for ED and can be extended to additional psychiatric illnesses. The proposed research uses highly innovative methods; intensive longitudinal data collected with mobile technology is combined with state-of-the art idiographic modeling methods to deliver a virtual, personalized treatment. This proposal integrates assessment of broad (e.g., SDOH; public health burden) and specific (e.g., ED symptoms) outcomes, to ensure that social context can be integrated into personalization. The proposed research has high clinical impact. Ultimately, this proposal will lead directly to the creation and dissemination of an evidence-based individually-personalized treatment for EDs, as well as will serve as an exemplar for precision treatment development across the entire field of psychiatry.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Enhanced Cognitive Behavioral Therapy for Eating Disorders?
Recent studies suggest that Enhanced Cognitive Behavioral Therapy (CBT-E) is promising for treating eating disorders, including bulimia nervosa, by addressing fears related to food and body image. However, up to 44% of individuals with bulimia may experience worsening symptoms after standard CBT, indicating a need for personalized approaches like CBT-E.12345
Is Enhanced Cognitive Behavioral Therapy for Eating Disorders safe for humans?
What makes the Transdiagnostic Network Informed Personalized Treatment for Eating Disorders unique compared to other treatments?
Research Team
Cheri A Levinson, PhD
Principal Investigator
University of Louisville
Eligibility Criteria
This trial is for adults aged 18-65 with an active eating disorder, excluding ARFID. It's not suitable for individuals who are currently experiencing suicidal thoughts, mania, or psychosis.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase I: Ecological Momentary Assessment
Participants undergo two weeks of ecological momentary assessment to characterize individual mechanisms of treatment
Phase II: Treatment
Participants receive 10 sessions of either Enhanced Cognitive Behavioral Therapy for Eating Disorders (CBT-E) or personalized treatment based on ecological momentary assessment surveys
Relapse Prevention
Participants complete one session of relapse prevention at the end of the treatment phase
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Enhanced Cognitive Behavioral Therapy for Eating Disorders
- Transdiagnostic Network Informed Personalized Treatment
Enhanced Cognitive Behavioral Therapy for Eating Disorders is already approved in United States, European Union for the following indications:
- Anorexia Nervosa
- Bulimia Nervosa
- Binge Eating Disorder
- Other Specified Feeding or Eating Disorder
- Anorexia Nervosa
- Bulimia Nervosa
- Binge Eating Disorder
- Other Specified Feeding or Eating Disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Louisville
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator